DOCSLIB.ORG

19F Henry Ford Health System Publication List – May 2021 This

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
19F Henry Ford Health System Publication List – May 2021 This 19f Henry Ford Health System Publication List – May 2021 This bibliography aims to recognize the scholarly activity and provide ease of access to journal articles, meeting abstracts, book chapters, books and other works published by Henry Ford Health System personnel. Searches were conducted in PubMed, Embase, and Web of Science during the month, and then imported into EndNote for formatting. There are 144 unique citations listed this month, with 8 articles and 5 conference abstracts on COVID-19. Articles are listed first, followed by conference abstracts, books and book chapters, and a bibliography of publications on COVID-19. Because of various limitations, this does not represent an exhaustive list of all published works by Henry Ford Health System authors. Click the “Full Text” link to view the articles to which Sladen Library provides access. If the full- text of the article is not available, you may request it through ILLiad by clicking on “Request Article,” or calling us at (313) 916-2550. If you would like to be added to the monthly email distribution list to automatically receive a PDF of this bibliography, or you have any questions or comments, please contact [email protected]. If your published work has been missed, please use this form to notify us for inclusion on next month’s list. All articles and abstracts listed here are deposited into Scholarly Commons, the HFHS institutional repository. Jump to: Articles Administration Neurology Allergy and Immunology Neurosurgery Anesthesiology Obstetrics, Gynecology and Women’s Behavioral Health Services/Psychiatry Health Services Cardiology/Cardiovascular Research Ophthalmology and Eye Care Services Center for Health Policy and Health Orthopedics/Bone and Joint Center Services Research Otolaryngology – Head and Neck Surgery Center for Individualized and Genomic Pathology and Laboratory Medicine Medicine Research Pediatrics Dermatology Pharmacy Diagnostic Radiology Public Health Sciences Emergency Medicine Pulmonary and Critical Care Medicine Endocrinology and Metabolism Radiation Oncology Gastroenterology Research Administration Hematology-Oncology Rheumatology Infectious Diseases Sleep Medicine Internal Medicine Surgery Nephrology Urology Conference Abstracts Administration Emergency Medicine Cardiology/Cardiovascular Research Infectious Diseases Center for Individualized and Genomic Internal Medicine Medicine Research Public Health Sciences Dermatology Articles Administration Fortin CN, Jiang C, Caldwell MT, As-Sanie S, Dalton V, and Marsh EE. Trends in Emergency Department Utilization Among Women With Leiomyomas in the United States. Obstet Gynecol 2021; 137(5):897-905. PMID: 33831918. Full Text Division of Reproductive Endocrinology and Infertility and the Division of Gynecology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, and the Department of Emergency Medicine, Henry Ford Hospital, Detroit, Michigan. OBJECTIVE: To describe trends in emergency department (ED) visits in the United States with a primary diagnosis of leiomyomas, subsequent admissions, and associated charges. METHODS: The Healthcare Cost and Utilization Project Nationwide Emergency Department Sample database was used to retrospectively identify all ED visits from 2006 to 2017 among women aged 18-55 years with a primary diagnosis of leiomyomas as indicated by International Classification of Diseases (ICD) diagnosis codes. Trends in ED visits and subsequent admissions were analyzed and stratified by patient and hospital characteristics. Secondary ICD codes, Current Procedural Terminology codes, and hospital charges were analyzed. A multivariate regression model was used to identify predictors of admission. RESULTS: Although the number of ED visits for leiomyomas increased from 28,732 in 2006 to 65,685 in 2017, the admission rate decreased, from 23.9% in 2006 to 11.1% in 2017. Emergency department visits for leiomyomas were highest among women who were aged 36-45 years (44.5%), in the lowest income quartile (36.1%), privately insured (38.3%), and living in the South (46.2%). Admission was more likely at nonteaching hospitals (odds ratio [OR] 1.23, 95% CI 1.08-1.39) or those located in the Northeast (OR 1.39, 95% CI 1.15-1.68). Patient characteristics associated with admission included older age (26-35 years: OR 1.42, 95% CI 1.21-1.66; 36-45 years: OR 2.01, 95% CI 1.72-2.34; 46-55 years: OR 2.60, 95% CI 2.23-3.03) and bleeding-related complaints (OR 14.92, 95% CI 14.00-15.90). Admission was least likely in uninsured patients (Medicare: OR 1.37, 95% CI 1.21-1.54; Medicaid: OR 1.26, 95% CI 1.16-1.36; private: OR 1.44, 95% CI 1.32-1.56). CONCLUSION: Although ED visits for leiomyomas are increasing, admission rates for these visits are decreasing. The substantial decline in admissions suggests many of these visits could potentially be addressed in a non-acute-care setting. However, when women with leiomyomas present with a bleeding-related complaint, the odds of admission increase 15-fold. There is an apparent disparity in likelihood of admission based on insurance type. Allergy and Immunology Altman MC, Flynn K, Rosasco MG, Dapas M, Kattan M, Lovinsky-Desir S, O'Connor GT, Gill MA, Gruchalla RS, Liu AH, Pongracic JA, Khurana Hershey GK, Zoratti EM, Teach SJ, Rastrogi D, Wood RA, Bacharier LB, LeBeau P, Gergen PJ, Togias A, Busse WW, Presnell S, Gern JE, Ober C, and Jackson DJ. Inducible expression quantitative trait locus analysis of the MUC5AC gene in asthma in urban populations of children. J Allergy Clin Immunol 2021; Epub ahead of print. PMID: 34019912. Full Text Department of Medicine, University of Washington, Seattle WA; Benaroya Research Institute, Seattle WA. Electronic address: [email protected]. Benaroya Research Institute, Seattle WA. Department of Human Genetics, University of Chicago, Chicago, IL. Columbia University, New York NY. Boston University School of Medicine, Boston MA. UT Southwestern Medical Center, Dallas TX. Children's Hospital Colorado University of Colorado School of Medicine, Aurora CO. Ann Robert H Lurie Children's Hospital of Chicago, Chicago IL. Cincinnati Children's Hospital Cincinnati OH. Henry Ford Health System Detroit MI. Children's National Hospital, Washington DC. Department of Pediatrics, Johns Hopkins University Medical Center, Baltimore, MD. Washington University, Saint Louis MO. Rho Inc, Chapel Hill NC. NIH/NIAID, Bethesda MD. University of Wisconsin School of Medicine and Public Health, Madison WI. BACKGROUND: Mucus plugging can worsen asthma control, lead to reduced lung function and fatal exacerbations. MUC5AC is the secretory mucin implicated in mucus plugging, and MUC5AC gene expression has been associated with development of airway obstruction and asthma exacerbations in urban children with asthma. However, the genetic determinants of MUC5AC expression are not established. OBJECTIVE: To assess single-nucleotide polymorphisms (SNPs) that influence MUC5AC expression and relate to pulmonary functions in childhood asthma. METHODS: We used RNA- sequencing data from upper airway samples and performed cis-expression quantitative trait loci (eQTL) and allele specific expression (ASE) analyses in two cohorts of predominantly Black and Hispanic urban children, a high asthma-risk birth cohort and an exacerbation-prone asthma cohort. We further investigated inducible MUC5AC eQTLs during incipient asthma exacerbations. We tested significant eQTLs SNPs for associations with lung function measurements and investigated their functional consequences in DNA regulatory databases. RESULTS: We identified two independent groups of SNPs in the MUC5AC gene that were significantly associated with MUC5AC expression. Moreover, these SNPs showed stronger eQTL associations with MUC5AC expression during asthma exacerbations, consistent with inducible expression. SNPs in one group also showed significant association with decreased pulmonary functions. These SNPs included multiple EGR1 transcription factor binding sites suggesting a mechanism of effect. CONCLUSIONS: These findings demonstrate the applicability of organ specific RNA-sequencing data to determine genetic factors contributing to a key disease pathway. Specifically, they suggest important genetic variations that may underlie propensity to mucus plugging in asthma and could be important in targeted asthma phenotyping and disease management strategies. Allergy and Immunology Eapen AA, and Kim H. The Phenotype of the Food-Allergic Patient. Immunol Allergy Clin North Am 2021; 41(2):165-175. PMID: 33863477. Full Text Division of Allergy and Clinical Immunology, Henry Ford Health System, 1 Ford Place, Detroit, MI 48202, USA. Electronic address: [email protected]. Division of Allergy and Clinical Immunology, Henry Ford Health System, 1 Ford Place, Detroit, MI 48202, USA. Food allergy's increasing prevalence across the globe has initiated research into risk factors associated with the disease and coexistence with other allergic diseases. Longitudinal birth cohorts have identified food allergy phenotypes of patients based on genetic background, racial diversity, and environmental factors. Identifying food sensitization patterns and coexistence of other allergic diseases allows physicians to provide appropriate care for food allergy and personalized anticipatory guidance for the appearance of other allergic diseases. The authors seek to detail key findings of 4 longitudinal allergy birth cohorts that investigate food allergy and other allergic diseases to further characterize food allergy
Load more

Recommended publications
  • Acne Class Update
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-2596 Drug Class Update with New Drug Evaluation: Acne Drugs Date of Review: June 2020 Date of Last Review: November 2018 Dates of Literature Search: 08/03/2018 - 12/26/2019 Generic Name: Trifarotene Brand Name (Manufacturer): Aklief® (Galderma Laboratories, LP) Dossier Received: no Current Status of PDL Class: See Appendix 1. Purpose for Class Update: The acne class has had one new approval, trifarotene cream, and several new product formulations since it was last reviewed in 2018. The purpose of this update is to evaluate new comparative evidence for trifarotene cream for the treatment of acne vulgaris and any new data on comparative efficacy or harms in the acne class since the previous update. Acne conglobata, acne fulminans, and severe cystic acne are covered conditions under the Oregon Health Plan (OHP). Research Questions: 1. What is the comparative efficacy and effectiveness of treatments for severe acne (topical agents of adapalene, adapalene/benzoyl peroxide, tretinoin, tazarotene, benzoyl peroxide, salicylic acid, dapsone, azelaic acid, clindamycin, erythromycin, minocycline, sulfacetamide, trifarotene; oral systemic antibiotics of doxycycline, minocycline, tetracycline, azithromycin, erythromycin, clindamycin, trimethoprim, and sulfamethoxazole/trimethoprim; hormonal agents of oral contraceptives and spironolactone; and oral isotretinoin)? 2. What are the comparative harms of treatments for severe acne? 3. Are there subpopulations of patients in which a particular treatment for severe acne would be more effective or associated with less harm? Conclusions: There are no new high-quality clinical practice guidelines which have evaluated comparative efficacy and safety of treatments for acne vulgaris.
    [Show full text]
  • DRUG and MEDICAL DEVICE HIGHLIGHTS Helping You Maintain and Improve Your Health 2019
    DRUG AND MEDICAL DEVICE HIGHLIGHTS Helping you maintain and improve your health 2019 DRUG AND MEDICAL DEVICE HIGHLIGHTS 2019 Helping you maintain and improve your health Learn about the new drugs and medical devices that Health Canada approved for sale in Canada, the information we published about potential safety issues, and our other accomplishments in 2019. Health Canada is the federal department responsible for helping the people of Canada maintain and improve their health. Health Canada is committed to improving the lives of all of Canada’s people and to making this country’s population among the healthiest in the world as measured by longevity, lifestyle and effective use of the public health care system. Également disponible en français sous le titre : Préserver et améliorer votre santé : Faits saillants sur les médicaments et les instruments médicaux 2019 To obtain additional information, please contact: Health Canada Address Locator 0900C2 Ottawa, ON K1A 0K9 Tel.: 613-957-2991 Toll free: 1-866-225-0709 Fax: 613-941-5366 TTY: 1-800-465-7735 E-mail: [email protected] © Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2020 Publication date: May 2020 This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged. Cat.: H161-11E-PDF ISSN: 2562-9816 Pub.: 190484 CONTENTS WELCOME TO OUR 2019 HIGHLIGHTS REPORT ..........................................................................................1 MESSAGE FROM THE CHIEF MEDICAL
    [Show full text]
  • 2020 Research Annual Report Table of Contents
    2020 RESEARCH ANNUAL REPORT TABLE OF CONTENTS PART I – INTERNAL MEDICINE DEPARTMENT ALLERGY AND IMMUNOLOGY ...................................................................................... 1 CARDIOLOGY/CARDIOVASCULAR RESEARCH…………………………………………..2 ENDOCRINOLOGY AND METABOLISM ........................................................................ 3 GASTROENTEROLOGY ................................................................................................ 5 HYPERTENSION AND VASCULAR RESEARCH……………………………………….…...6 PULMONARY……………………………………………………………………………………10 SLEEP MEDICINE………………………………………………………………………………10 GENERAL INTERNAL MEDICINE…………………………………………………….………12 HEMATOLOGY/ONCOLOGY………………………………………………………………….12 PART II – ALL OTHER CLINICAL DEPARTMENTS DERMATOLOGY ......................................................................................................... .14 EMERGENCY MEDICINE……………………………………………………………………..17 NEUROLOGY…………………………………………………………………………………...19 NEUROSURGERY……………………………………………………………………………… ORTHOPAEDICS/BONE & JOINT…………………………………………………………….31 OTOLARYNGOLOGY………………………………………………………………………… .36 PATHOLOGY ................................................................................................................ .36 PEDIATRICS…………………………………………………………………………………….37 PSYCHIATRY/BEHAVORIAL HEALTH………………………………………………………38 RADIATION ONCOLOGY ............................................................................................. 39 UROLOGY………………………………………………………………………………………40 WOMEN’S HEALTH……………………………………………………………………………42 i PART III POPULATION
    [Show full text]
  • A20-73 Trifarotene (Acne Vulgaris) – Benefit Assessment According to §35A Social Code Book V1
    IQWiG Reports – Commission No. A20-73 Trifarotene (acne vulgaris) – Benefit assessment according to §35a Social Code Book V1 Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Trifaroten (Acne vulgaris) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 November 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract of dossier assessment A20-73 Version 1.0 Trifarotene (acne vulgaris) 12 November 2020 Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Trifarotene (acne vulgaris) – Benefit assessment according to §35a Social Code Book V Commissioning agency Federal Joint Committee Commission awarded on 13 August 2020 Internal Commission No. A20-73 Address of publisher Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: [email protected] Internet: www.iqwig.de Institute for Quality and Efficiency in Health Care (IQWiG) - i - Extract of dossier assessment A20-73 Version 1.0 Trifarotene (acne vulgaris) 12 November 2020 Medical and scientific advice . Prof. Dr. med. Dr. rer. nat. Enno Schmidt, University Hospital Schleswig-Holstein, Lübeck, Germany IQWiG thanks the medical and scientific advisor for his contribution to the dossier assessment. However, the advisor was not involved in the actual preparation of the dossier assessment. The responsibility for the contents of the dossier assessment lies solely with IQWiG. IQWiG employees involved in the dossier assessment . Anke Penno . Katharina Biester . Moritz Felsch .
    [Show full text]
  • Aars Hot Topics Member Newsletter
    AARS HOT TOPICS MEMBER NEWSLETTER American Acne and Rosacea Society 201 Claremont Avenue • Montclair, NJ 07042 (888) 744-DERM (3376) • [email protected] www.acneandrosacea.org Like Our YouTube Page Visit acneandrosacea.org to Become an AARS Member and TABLE OF CONTENTS Donate Now on acneandrosacea.org/donate AARS News Register Now for the AARS 9th Annual Scientific Symposium .................................... 2 Our Officers AARS BoD Member Emmy Graber invites you to earn free CME! ............................. 3 J. Mark Jackson, MD AARS President New Medical Research The effect of 577-nm pro-yellow laser on demodex density in patients with rosacea 4 Andrea Zaenglein, MD Aspirin alleviates skin inflammation and angiogenesis in rosacea ............................. 4 AARS President-Elect Efficacy and safety of intense pulsed light using a dual-band filter ............................ 4 Split-face comparative study of fractional Er:YAG laser ............................................. 5 Joshua Zeichner, MD Evaluation of biophysical skin parameters and hair changes ..................................... 5 AARS Treasurer Dermal delivery and follicular targeting of adapalene using PAMAM dendrimers ...... 6 Therapeutic effects of a new invasive pulsed-type bipolar radiofrequency ................ 6 Bethanee Schlosser, MD Efficacy and safety of a novel water-soluble herbal patch for acne vulgaris .............. 6 AARS Secretary A clinical study evaluating the efficacy of topical bakuchiol ........................................ 7 Tolerability and efficacy of clindamycin/tretinoin versus adapalene/benzoyl peroxide7 James Del Rosso, DO Photothermal therapy using gold nanoparticles for acne in Asian patients ................ 8 Director Development of a novel freeze-dried mulberry leaf extract-based transfersome gel . 8 The efficacy and safety of dual-frequency ultrasound for improving skin hydration ... 9 Emmy Graber, MD Director Clinical Reviews Jonathan Weiss, MD What the pediatric and adolescent gynecology clinician needs to know about acne .
    [Show full text]
  • 213433Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213433Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA/BLA Multidisciplinary Review and Evaluation: NDA 213433 WINLEVI (clascoterone) cream, 1% NDA Multidisciplinary Review and Evaluation Application Type NME- In “The Program” Application Number(s) NDA 213433 Priority or Standard Standard Submit Date(s) August 19, 2019 Received Date(s) August 27, 2019 PDUFA Goal Date August 27, 2020 Division/Office Shari Targum, Deputy Director, Division of Dermatology and Dentistry Julie Beitz, Director Office of Immunology and Inflammation Review Completion Date Established/Proper Name Clascoterone cream, 1% (Proposed) Trade Name WINLEVI Pharmacologic Class NME Code Name N/A Applicant Cassiopea SpA Dosage Form Topical cream Applicant proposed Dosing Apply a thin layer (approximately 1 gram) to affected area Regimen twice daily (morning and evening) Applicant Proposed For the treatment of acne vulgaris in patients 9 years of age Indication(s)/Population(s) and older Applicant Proposed SNOMED CT Indication Disease Term for Each Proposed Indication Recommendation on Regulatory Action Approval Recommended For the treatment of acne vulgaris in patients 12 years of age Indication(s)/Population(s) and older (if applicable) Recommended SNOMED CT Indication Disease Term for Each Indication (if applicable) Recommended Dosing Apply a thin layer (approximately 1 gram) to affected area Regimen twice daily (morning and
    [Show full text]
  • Kaiser Permanente Bernard J. Tyson School of Medicine, Inc. Exclusive Provider Organization (EPO) Student Blanket Health Plan Drug Formulary
    Kaiser Permanente Bernard J. Tyson School of Medicine, Inc. Exclusive Provider Organization (EPO) Student Blanket Health Plan Drug Formulary Effective September 1, 2021 Health Plan Products: Kaiser Permanente Bernard J. Tyson School of Medicine, EPO Student Blanket Health Plan offered by Kaiser Permanente Insurance Company For the most current list of covered medications or for help understanding your KPIC insurance plan benefits, including cost sharing for drugs under the prescription drug benefit and under the medical benefit: Call 1-800-533-1833, TTY 711, Monday through Friday, 7 a.m. to 9 p.m. ET Visit kaiserpermanente.org to: • Find a participating retail pharmacy by ZIP code. • Look up possible lower-cost medication alternatives. • Compare medication pricing and options. • Find an electronic copy of the formulary here. • Get plan coverage information. For cost sharing information for the outpatient prescription drug benefits in your specific plan, please visit kp.org/kpic-websiteTBD The formulary is subject to change and all previous versions of the formulary are no longer in effect. Kaiser Permanente Last updated: September 1, 2021 Table of Contents Informational Section...........................................................................................................................................3 ANTIHISTAMINE DRUGS - Drugs for Allergy.....................................................................................................9 ANTI-INFECTIVE AGENTS - Drugs for Infections...........................................................................................
    [Show full text]
  • To Download the AARS Hot Topics Newsletter
    AARS HOT TOPICS MEMBER NEWSLETTER American Acne and Rosacea Society 201 Claremont Avenue • Montclair, NJ 07042 (888) 744-DERM (3376) • [email protected] www.acneandrosacea.org Like Our YouTube Page We encourage you to TABLE OF CONTENTS invite your colleagues and patients to get active in AARS Special Announcements th the American Acne & Register for the 14 Annual Networking Reception at AAD ............................................2 Rosacea Society! Visit AARS Grantee publication ...................................................................................................2 www.acneandrosacea.org to become member and New Medical Research donate now on Gender- and age-related differences in facial sebaceous glands in Asian skin ......... 2 www.acneandrosacea.org/ A microtube array membrane (MTAM) encapsulated live fermenting ........................ 3 donate to continue to see Tranexamic acid ameliorates rosacea symptoms ....................................................... 3 a change in acne and Treatment of acne with a combination of propolis, tea tree oil, and aloe vera ........... 3 rosacea. New study to assess treatments for antibiotic-resistant skin infections ...................... 4 Microneedling by dermapen and glycolic acid peel for the treatment of acne scars .. 4 Association of caffeine intake and caffeinated coffee consumption ........................... 5 Association between market competition and prices of generic topical ..................... 5 BPX-01 minocycline topical gel shows promise for the treatment .............................
    [Show full text]
  • Mississippi Division of Medicaid Universal Preferred Drug List
    MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2021 UNIVERSAL PREFERRED DRUG LIST Version 2021.13a Updated: 8-30-2021 (For All Medicaid, MSCAN and CHIP Beneficiaries) Conduent’s SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid’s PA criteria. THERAPEUTIC PREFERRED AGENTS NON-PREFERRED AGENTS PA CRITERIA DRUG CLASS ACNE AGENTS ANTI-INFECTIVE clindamycin gel (generic Cleocin-T) ACZONE (dapsone) Maximum Age Limit clindamycin lotion AKNE-MYCIN (erythromycin) • 21 years – all agents except clindamycin solution azelaic acid isotretinoins AMZEEQ FOAM (minocycline) AZELEX (azelaic acid) CLEOCIN-T (clindamycin) CLINDAMYCIN PAC (clindamycin) CLINDAGEL (clindamycin) clindamycin foam clindamycin gel daily (generic Clindagel) dapsone ERY (erythromycin) ERYGEL (erythromycin) erythromycin gel, swabs, solution EVOCLIN (clindamycin) KLARON (sulfacetamide) sulfacetamide RETINOIDS RETIN-A (tretinoin) adapalene tretinoin cream AKLIEF (trifarotene) ALTRENO (tretinoin) ARAZLO (tazarotene) ATRALIN (tretinoin) AVITA (tretinoin) DIFFERIN (adapalene) FABIOR (tazarotene) PLIXDA (adapalene) 1 Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act.This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.
    [Show full text]
  • Clinical Policy: Topical Agents: Acne Preparations
    Clinical Policy: Topical Agents: Acne Preparations Reference Number: OH.PHAR.PPA.89 Effective Date: 01.20 Revision Log Last Review Date: 07.20 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description ANTIBIOTIC PRODUCTS NO PA REQUIRED “PREFERRED” PA REQUIRED “NON-PREFERRED” CLINDAMYCIN gel (generic of Cleocin T®, Clindamax®) AMZEEQ™ foam (minocycline) CLINDAMYCIN lotion (generic of Cleocin T®, Clindamax®) CLINDACIN® Pak (clindamycin/skin cleanser kit) CLINDAMYCIN solution (generic of Cleocin T®) CLINDAMYCIN foam (generic of Evoclin®) ERYTHROMYCIN gel CLINDAMYCIN pledgets (generic of Cleocin T®) ERYTHROMYCIN solution (generic of A/T/S®, Akne- ERYTHROMYCIN pads (generic of Ery Pads®) Mycin®) ACNE PREPARATIONS – OTHER PRODUCTS NO PA REQUIRED “PREFERRED” PA REQUIRED “NON-PREFERRED” AZELEX® cream (azelaic acid) ACZONE® gel (dapsone) FINACEA® gel (azelaic acid) BENZOYL PEROXIDE AND COMBINATION PRODUCTS NO PA REQUIRED “PREFERRED” PA REQUIRED “NON-PREFERRED” CLINDAMYCIN-BENZOYL PEROXIDE gel (generic of ACANYA® (clindamycin-benzoyl peroxide) Benzaclin®, Duac®) BENZOYL PEROXIDE foam (generic of Benzefoam®) BENZOYL PEROXIDE cleanser 5%, 6% & 10% ONEXTONTM gel (clindamycin-benzoyl peroxide) BENZOYL PEROXIDE gel 2.5%, 5%, 10% BPO (benzoyl peroxide) Gel 4% & 8% BENZOYL PEROXIDE wash (generic of Benzac AC ®, Benzac W®, Brevoxyl®, Desquam-X®, Pacnex®) ERYTHROMYCIN-BENZOYL PEROXIDE gel (generic of Benzamycin®) NEUAC® gel (clindamycin-benzoyl peroxide) PANOXYL® 10% foam, wash
    [Show full text]
  • 2021 Aetna Pharmacy Drug Guide
    Plan for your best health Advanced Control Plan - Aetna: Federal Employees Aetna.com Health benefits and health insurance plans are offered, administered and/or underwritten by Aetna Health Inc., Aetna Health Insurance Company of New York, Aetna HealthAssurance Pennsylvania Inc., Aetna Health Insurance Company and/or Aetna Life Insurance Company (Aetna). In Florida, by Aetna Health Inc. and/or Aetna Life Insurance Company. In Utah and Wyoming by Aetna Health of Utah Inc. and Aetna Life Insurance Company. In Maryland, by Aetna Health Inc., 151 Farmington Avenue, Hartford, CT 06156. Each insurer has sole financial responsibility for its own products. 2021 Pharmacy Drug Guide - Advanced Control Plan - Aetna: Federal Employees Table of Contents INFORMATIONAL SECTION..................................................................................................................4 ANALGESICS........................................................................................................................................... 14 ANTIDOTES AND SPECIFIC ANTAGONISTS.................................................................................... 25 ANTI-INFECTIVES..................................................................................................................................25 ANTINEOPLASTIC AGENTS................................................................................................................. 41 ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES..................................................................... 49
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]